Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4238796 | 1.00 | HTR6 (0.48) | HTR6SMN1; SMN2 | |
| SCHEMBL994546 | 1.00 | HTR6 (0.48) | HTR6SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1190497 | 0.98 | HTR6 (0.47) | HTR6SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL311292 | 0.98 | HTR6 (0.47) | HTR6SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL20528061 | 0.98 | HTR6 (0.47) | HTR6SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3649582 | 0.98 | HTR6 (0.47) | HTR6SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL2033780 | 0.98 | HTR6 (0.47) | HTR6SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1726824 | 0.98 | HTR6 (0.47) | HTR6SMN1; SMN2 | |
| SCHEMBL18091509 | 0.82 | HTR6 (0.57) | HTR6SMN1; SMN2 | |
| SCHEMBL19990312 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 533 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4554939-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2025-05-21 | — | — | EP | claimed |
| CN-119604494-A | PCSK9 inhibitors and methods of use thereof | 阿斯利康(瑞典)有限公司 | 2025-03-11 | — | — | CN | claimed |
| WO-2024013209-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-01-18 | — | — | WO | claimed |
| EP-3911640-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2021-11-24 | — | — | EP | claimed |
| EP-3911648-A2 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2021-11-24 | — | — | EP | claimed |
| US-11046699-B2 | Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses | RAPT THERAPEUTICS, INC. (US) | 2021-06-29 | — | — | US | claimed |
| WO-2020150474-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | DOGMA THERAPEUTICS, INC. (US) | 2020-07-23 | — | — | WO | claimed |
| WO-2020150473-A2 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | DOGMA THERAPEUTICS, INC. (US) | 2020-07-23 | — | — | WO | claimed |
| EP-2790511-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2014-10-22 | — | — | EP | claimed |
| WO-2013090271-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2013-06-20 | — | — | WO | claimed |
| EP-1899318-A1 | NEW AZETIDINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS FOR THE TREATMENT OF GASTROINTESTINAL DISEASES | AstraZeneca AB (SE) | 2008-03-19 | — | — | EP | claimed |
| WO-2006137791-A1 | NEW AZETIDINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS FOR THE TREATMENT OF GASTROINTESTINAL DISEASES | ASTRAZENECA AB (SE) | 2006-12-28 | — | — | WO | claimed |
| WO-2026102212-A1 | MACROCYCLIC MCL-1 INHIBITORS | VANDERBILT UNIVERSITY (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-3911640-B1 | PCSK9 INHIBITORS FOR USE IN THERAPY, ESPECIALLY THE TREATMENT OF CARDIOVASCULAR DISEASE | ASTRAZENECA AB (SE) | 2026-05-13 | — | — | EP | disclosed |
| US-12584120-B2 | PCSK9 inhibitors and methods of use thereof | ASTRAZENECA AB (SE) | 2026-03-24 | — | — | US | disclosed |
| EP-4695254-A1 | SUBSTITUTED 6-IMIDAZOPYRIDAZINE IL-17A MODULATORS AND USES THEREOF | Dice Alpha, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-1342717-A1 | BENZIMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-09-10 | — | — | EP | disclosed |
| US-4681938-A | Novel polycyclic hydrazones of rifamycins, their manufacture, and their pharmaceutical compositions for treating tuberculosis | CIBA-GEIGY CORPORATION (US) | 1987-07-21 | — | — | US | disclosed |
| US-4551450-A | ANTITUBERCULOTIC AGENTS | CIBA-GEIGY CORPORATION (US) | 1985-11-05 | — | — | US | disclosed |
| EP-0135837-A2 | Polycyclic hydrazones, process for their preparation, pharmacetical compositions thereof and their use | CIBA-GEIGY AG (CH) | 1985-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12584120-B2 | PCSK9 inhibitors and methods of use thereof | PCSK9, LDLR, PCSK7 | HTR6 1424/4885SMN1; SMN2 3043/4885 |
| US-11046699-B2 | Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses | GLS, GLS2, TK2 | HTR6 1183/4885SMN1; SMN2 2846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.